{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:00:27Z","timestamp":1791050427490,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pompe disease (PD) is a rare autosomal recessive glycogen storage disorder that causes proximal muscle weakness and loss of respiratory function. While enzyme replacement therapy (ERT) is the only effective treatment, biomarkers for disease monitoring are scarce. Following ex vivo biomarker validation in phantom studies, we apply multispectral optoacoustic tomography (MSOT), a laser- and ultrasound-based non-invasive imaging approach, in a clinical trial (NCT05083806) to image the biceps muscles of 10 late-onset PD (LOPD) patients and 10 matched healthy controls. MSOT is compared with muscle magnetic resonance imaging (MRI), ultrasound, spirometry, muscle testing and quality of life scores. Next, results are validated in an independent LOPD patient cohort from a second clinical site. Our study demonstrates that MSOT enables imaging of subcellular disease pathology with increases in glycogen\/water, collagen and lipid signals, providing higher sensitivity in detecting muscle degeneration than current methods. This translational approach suggests implementation in the complex care of these rare disease patients.<\/jats:p>","DOI":"10.1038\/s41467-024-52143-6","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T01:01:56Z","timestamp":1725757316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Lina","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-5319","authenticated-orcid":false,"given":"Jana","family":"Zsch\u00fcntzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alica","family":"Stobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bruex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8244-1261","authenticated-orcid":false,"given":"Adrian P.","family":"Regensburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Cla\u00dfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6258-5409","authenticated-orcid":false,"given":"Frauke","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"J\u00fcngert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Rother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-4711","authenticated-orcid":false,"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Danko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4114-7589","authenticated-orcid":false,"given":"Werner","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"T\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Vorgerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Schlaffke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Woelfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-4473","authenticated-orcid":false,"given":"Alexander","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Winterholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-8537","authenticated-orcid":false,"given":"Regina","family":"Trollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-5411","authenticated-orcid":false,"given":"Rafael","family":"Hei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Raming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3535-2626","authenticated-orcid":false,"given":"Ferdinand","family":"Knieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"52143_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani, P. S. et al. Pompe disease diagnosis and management guideline. Genet. Med. 8, 267\u2013288 (2006).","journal-title":"Genet. Med."},{"key":"52143_CR2","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/humu.20745","volume":"29","author":"M Kroos","year":"2008","unstructured":"Kroos, M. et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum. Mutat. 29, E13\u2013E26 (2008).","journal-title":"Hum. Mutat."},{"key":"52143_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler, L., Puertollano, R. & Raben, N. Pompe disease: from basic science to therapy. Neurotherapeutics 15, 928\u2013942 (2018).","journal-title":"Neurotherapeutics"},{"key":"52143_CR4","first-page":"304","volume":"76","author":"JC Pompe","year":"1932","unstructured":"Pompe, J. C. Over idiopathische hypertrophie van het hart. Ned. Tijdschr. Geneeskd. 76, 304\u2013311 (1932).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"52143_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj0860011","volume":"86","author":"HG Hers","year":"1963","unstructured":"Hers, H. G. \u03b1-Glucosidase deficiency in generalized glycogen-storage disease (Pompe\u2019s disease). Biochem. J. 86, 11\u201316 (1963).","journal-title":"Biochem. J."},{"key":"52143_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout, H. M. et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112, 332\u2013340 (2003).","journal-title":"Pediatrics"},{"key":"52143_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg, A. T. & Reuser, A. J. Pompe\u2019s disease. Lancet 372, 1342\u20131353 (2008).","journal-title":"Lancet"},{"key":"52143_CR8","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","volume":"144","author":"PS Kishnani","year":"2004","unstructured":"Kishnani, P. S. & Howell, R. R. Pompe disease in infants and children. J. Pediatr. 144, S35\u2013S43 (2004).","journal-title":"J. Pediatr."},{"key":"52143_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler, E. J. et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45, 319\u2013333 (2012).","journal-title":"Muscle Nerve"},{"key":"52143_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2013.08.005","volume":"110","author":"N Preisler","year":"2013","unstructured":"Preisler, N. et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Mol. Genet. Metab. 110, 287\u2013289 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"52143_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N. Engl. J. Med. 362, 1396\u20131406 (2010).","journal-title":"N. Engl. J. Med."},{"key":"52143_CR12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","volume":"22","author":"AA Khan","year":"2020","unstructured":"Khan, A. A. et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet. Med. 22, 898\u2013907 (2020).","journal-title":"Genet. Med."},{"key":"52143_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J. Neurol. 264, 621\u2013630 (2017).","journal-title":"J. Neurol."},{"key":"52143_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser, B. et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 20, 1027\u20131037 (2021).","journal-title":"Lancet Neurol."},{"key":"52143_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2147\/TCRM.S334232","volume":"18","author":"C Bolano-Diaz","year":"2022","unstructured":"Bolano-Diaz, C. & Diaz-Manera, J. Therapeutic options for the management of Pompe disease: current challenges and clinical evidence in therapeutics and clinical risk management. Ther. Clin. Risk Manag. 18, 1099\u20131115 (2022).","journal-title":"Ther. Clin. Risk Manag."},{"key":"52143_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.c.31321","volume":"160C","author":"LE Case","year":"2012","unstructured":"Case, L. E., Beckemeyer, A. A. & Kishnani, P. S. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am. J. Med. Genet. C Semin. Med. Genet. 160C, 69\u201379 (2012).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"52143_CR17","doi-asserted-by":"crossref","first-page":"768-e31","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A. T. et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur. J. Neurol. 24, 768-e31 (2017).","journal-title":"Eur. J. Neurol."},{"key":"52143_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1017\/cjn.2016.37","volume":"43","author":"M Tarnopolsky","year":"2016","unstructured":"Tarnopolsky, M. et al. Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel. Can. J. Neurol. Sci. 43, 472\u2013485 (2016).","journal-title":"Can. J. Neurol. Sci."},{"key":"52143_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/0004-282X20150194","volume":"74","author":"JC Llerena Junior","year":"2016","unstructured":"Llerena Junior, J. C. et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease. Arq. Neuropsiquiatr. 74, 166\u2013176 (2016).","journal-title":"Arq. Neuropsiquiatr."},{"key":"52143_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0412-3","volume":"15","author":"MENA Pompe Working Group.","year":"2015","unstructured":"MENA Pompe Working Group. Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group. BMC Neurol. 15, 205 (2015).","journal-title":"BMC Neurol."},{"key":"52143_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","volume":"35","author":"V Manwaring","year":"2012","unstructured":"Manwaring, V. et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J. Inherit. Metab. Dis. 35, 311\u2013316 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"52143_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","volume":"11","author":"SP Young","year":"2009","unstructured":"Young, S. P. et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet. Med. 11, 536\u2013541 (2009).","journal-title":"Genet. Med."},{"key":"52143_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","volume":"85","author":"Y An","year":"2005","unstructured":"An, Y. et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol. Genet. Metab. 85, 247\u2013254 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"52143_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29170-7","volume":"8","author":"S Figueroa-Bonaparte","year":"2018","unstructured":"Figueroa-Bonaparte, S. et al. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Sci. Rep. 8, 10898 (2018).","journal-title":"Sci. Rep."},{"key":"52143_CR25","doi-asserted-by":"publisher","first-page":"e0163493","DOI":"10.1371\/journal.pone.0163493","volume":"11","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte, S. et al. Muscle MRI findings in childhood\/adult onset Pompe disease correlate with muscle function. PLoS ONE 11, e0163493 (2016).","journal-title":"PLoS ONE"},{"key":"52143_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mus.27021","volume":"62","author":"R Rehmann","year":"2020","unstructured":"Rehmann, R. et al. Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease. Muscle Nerve 62, 541\u2013549 (2020).","journal-title":"Muscle Nerve"},{"key":"52143_CR27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymgmr.2015.03.010","volume":"3","author":"KM Gruhn","year":"2015","unstructured":"Gruhn, K. M. et al. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Mol. Genet. Metab. Rep. 3, 58\u201364 (2015).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"52143_CR28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41591-019-0669-y","volume":"25","author":"AP Regensburger","year":"2019","unstructured":"Regensburger, A. P. et al. Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy. Nat. Med. 25, 1905\u20131915 (2019).","journal-title":"Nat. Med."},{"key":"52143_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40348-020-00095-4","volume":"7","author":"AP Regensburger","year":"2020","unstructured":"Regensburger, A. P., Wagner, A. L., Claussen, J., Waldner, M. J. & Knieling, F. Shedding light on pediatric diseases: multispectral optoacoustic tomography at the doorway to clinical applications. Mol. Cell Pediatr. 7, 3 (2020).","journal-title":"Mol. Cell Pediatr."},{"key":"52143_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2021.100315","volume":"25","author":"AP Regensburger","year":"2022","unstructured":"Regensburger, A. P. et al. Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. Photoacoustics 25, 100315 (2022).","journal-title":"Photoacoustics"},{"key":"52143_CR31","doi-asserted-by":"crossref","unstructured":"Tr\u00e4ger, A. P. et al. Hybrid ultrasound and single wavelength optoacoustic imaging reveals muscle degeneration in peripheral artery disease. Photoacoustics 35, 100579 (2023).","DOI":"10.1016\/j.pacs.2023.100579"},{"key":"52143_CR32","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1021\/cr9002566","volume":"110","author":"V Ntziachristos","year":"2010","unstructured":"Ntziachristos, V. & Razansky, D. Molecular imaging by means of multispectral optoacoustic tomography (MSOT). Chem. Rev. 110, 2783\u20132794 (2010).","journal-title":"Chem. Rev."},{"key":"52143_CR33","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1364\/OL.38.001404","volume":"38","author":"A Buehler","year":"2013","unstructured":"Buehler, A., Kacprowicz, M., Taruttis, A. & Ntziachristos, V. Real-time handheld multispectral optoacoustic imaging. Opt. Lett. 38, 1404\u20131406 (2013).","journal-title":"Opt. Lett."},{"key":"52143_CR34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1364\/AOP.8.000586","volume":"8","author":"S Manohar","year":"2016","unstructured":"Manohar, S. & Razansky, D. Photoacoustics: a historical review. Adv. Opt. Photon. 8, 586\u2013617 (2016).","journal-title":"Adv. Opt. Photon."},{"key":"52143_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pacs.2018.07.001","volume":"11","author":"MW Schellenberg","year":"2018","unstructured":"Schellenberg, M. W. & Hunt, H. K. Hand-held optoacoustic imaging: a review. Photoacoustics 11, 14\u201327 (2018).","journal-title":"Photoacoustics"},{"key":"52143_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pacs.2019.05.001","volume":"14","author":"I Steinberg","year":"2019","unstructured":"Steinberg, I. et al. Photoacoustic clinical imaging. Photoacoustics 14, 77\u201398 (2019).","journal-title":"Photoacoustics"},{"key":"52143_CR37","doi-asserted-by":"crossref","unstructured":"Regensburger, A. P., Brown, E., Kronke, G., Waldner, M. J. & Knieling, F. Optoacoustic imaging in inflammation. Biomedicines 9, 483 (2021).","DOI":"10.3390\/biomedicines9050483"},{"key":"52143_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1627","volume":"3","author":"K Wilson","year":"2012","unstructured":"Wilson, K., Homan, K. & Emelianov, S. Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging. Nat. Commun. 3, 618 (2012).","journal-title":"Nat. Commun."},{"key":"52143_CR39","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nmeth.3929","volume":"13","author":"J Weber","year":"2016","unstructured":"Weber, J., Beard, P. C. & Bohndiek, S. E. Contrast agents for molecular photoacoustic imaging. Nat. Methods 13, 639\u2013650 (2016).","journal-title":"Nat. Methods"},{"key":"52143_CR40","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/nprot.2011.351","volume":"6","author":"D Razansky","year":"2011","unstructured":"Razansky, D., Buehler, A. & Ntziachristos, V. Volumetric real-time multispectral optoacoustic tomography of biomarkers. Nat. Protoc. 6, 1121\u20131129 (2011).","journal-title":"Nat. Protoc."},{"key":"52143_CR41","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMc1612455","volume":"376","author":"F Knieling","year":"2017","unstructured":"Knieling, F. et al. Multispectral optoacoustic tomography for assessment of Crohn\u2019s disease activity. N. Engl. J. Med. 376, 1292\u20131294 (2017).","journal-title":"N. Engl. J. Med."},{"key":"52143_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2020.100220","volume":"21","author":"AL Wagner","year":"2021","unstructured":"Wagner, A. L. et al. Precision of handheld multispectral optoacoustic tomography for muscle imaging. Photoacoustics 21, 100220 (2021).","journal-title":"Photoacoustics"},{"key":"52143_CR43","doi-asserted-by":"crossref","unstructured":"Danko, V. et al. Hybrid reflected-ultrasound computed tomography versus B-mode-ultrasound for muscle scoring in spinal muscular atrophy. J. Neuroimaging. 33, 393\u2013403 (2023).","DOI":"10.1111\/jon.13081"},{"key":"52143_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben, N. et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159\u2013169 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"52143_CR45","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","volume":"94","author":"AJ McVie-Wylie","year":"2008","unstructured":"McVie-Wylie, A. J. et al. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 94, 448\u2013455 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"52143_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-1-6","volume":"1","author":"M Cardone","year":"2008","unstructured":"Cardone, M. et al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1, 6 (2008).","journal-title":"Pathogenetics"},{"key":"52143_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","volume":"80","author":"PS Kishnani","year":"2023","unstructured":"Kishnani, P. S. et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol. 80, 558\u2013567 (2023).","journal-title":"JAMA Neurol."},{"key":"52143_CR48","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben, N., Roberts, A. & Plotz, P. H. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 26, 45\u201348 (2007).","journal-title":"Acta Myol."},{"key":"52143_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","volume":"54","author":"YH Chien","year":"2013","unstructured":"Chien, Y. H., Hwu, W. L. & Lee, N. C. Pompe disease: early diagnosis and early treatment make a difference. Pediatr. Neonatol. 54, 219\u2013227 (2013).","journal-title":"Pediatr. Neonatol."},{"key":"52143_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","volume":"169","author":"CF Yang","year":"2016","unstructured":"Yang, C. F. et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J. Pediatr. 169, 174\u2013180.e171 (2016).","journal-title":"J. Pediatr."},{"key":"52143_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","volume":"35","author":"CI van Capelle","year":"2012","unstructured":"van Capelle, C. I. et al. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J. Inherit. Metab. Dis. 35, 317\u2013323 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"52143_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s41687-020-00245-2","volume":"4","author":"M Harfouche","year":"2020","unstructured":"Harfouche, M. et al. Use of the patient-reported outcomes measurement information system (PROMIS(R)) to assess late-onset Pompe disease severity. J. Patient Rep. Outcomes 4, 83 (2020).","journal-title":"J. Patient Rep. Outcomes"},{"key":"52143_CR53","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.nmd.2012.10.024","volume":"23","author":"NA van der Beek","year":"2013","unstructured":"van der Beek, N. A., Hagemans, M. L., van der Ploeg, A. T., van Doorn, P. A. & Merkies, I. S. The Rasch-built Pompe-specific activity (R-PAct) scale. Neuromuscul. Disord. 23, 256\u2013264 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"52143_CR54","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20, 1012\u20131026 (2021).","journal-title":"Lancet Neurol."},{"key":"52143_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JND-190426","volume":"7","author":"SM Salabarria","year":"2020","unstructured":"Salabarria, S. M. et al. Advancements in AAV-mediated gene therapy for Pompe disease. J. Neuromuscul. Dis. 7, 15\u201331 (2020).","journal-title":"J. Neuromuscul. Dis."},{"key":"52143_CR56","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","volume":"20","author":"BJ Byrne","year":"2011","unstructured":"Byrne, B. J. et al. Pompe disease gene therapy. Hum. Mol. Genet. 20, R61\u2013R68 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"52143_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","volume":"122","author":"MV Rairikar","year":"2017","unstructured":"Rairikar, M. V. et al. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T > G \u201clate-onset\u201d GAA variant. Mol. Genet. Metab. 122, 99\u2013107 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"52143_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jmd2.12174","volume":"57","author":"SA Fernandes","year":"2021","unstructured":"Fernandes, S. A. et al. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: clinical tools to evaluate severity of muscle disease. JIMD Rep. 57, 94\u2013101 (2021).","journal-title":"JIMD Rep."},{"key":"52143_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","volume":"38","author":"PG Carlier","year":"2015","unstructured":"Carlier, P. G. et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. J. Inherit. Metab. Dis. 38, 565\u2013572 (2015).","journal-title":"J. Inherit. Metab. Dis."},{"key":"52143_CR60","doi-asserted-by":"publisher","first-page":"e0190784","DOI":"10.1371\/journal.pone.0190784","volume":"13","author":"A Lollert","year":"2018","unstructured":"Lollert, A. et al. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy. PLoS ONE 13, e0190784 (2018).","journal-title":"PLoS ONE"},{"key":"52143_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.omtm.2017.09.002","volume":"7","author":"C Baligand","year":"2017","unstructured":"Baligand, C. et al. 13C\/31P MRS metabolic biomarkers of disease progression and response to AAV delivery of hGAA in a mouse model of Pompe disease. Mol. Ther. Methods Clin. Dev. 7, 42\u201349 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"52143_CR62","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.nmd.2022.07.132","volume":"32","author":"G Beha","year":"2022","unstructured":"Beha, G. et al. FP.19 Quantification of glycogen distribution in late-onset Pompe patients using 7 Tesla C13 NMR spectroscopy. Neuromuscul. Disord. 32, S73 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"52143_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41566-019-0417-3","volume":"13","author":"S Bohndiek","year":"2019","unstructured":"Bohndiek, S. Addressing photoacoustics standards. Nat. Photonics 13, 298\u2013298 (2019).","journal-title":"Nat. Photonics"},{"key":"52143_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2023.100539","volume":"32","author":"H Assi","year":"2023","unstructured":"Assi, H. et al. A review of a strategic roadmapping exercise to advance clinical translation of photoacoustic imaging: from current barriers to future adoption. Photoacoustics 32, 100539 (2023).","journal-title":"Photoacoustics"},{"key":"52143_CR65","unstructured":"Paulus, L. P. et al. Contrast-enhanced multispectral optoacoustic tomography for functional assessment of the gastrointestinal tract. Adv. Sci. 10, e2302562 (2023)."},{"key":"52143_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2023.100457","volume":"30","author":"LP Paulus","year":"2023","unstructured":"Paulus, L. P. et al. Multispectral optoacoustic tomography of the human intestine\u2014temporal precision and the influence of postprandial gastrointestinal blood flow. Photoacoustics 30, 100457 (2023).","journal-title":"Photoacoustics"},{"key":"52143_CR67","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.gastro.2016.05.047","volume":"151","author":"MJ Waldner","year":"2016","unstructured":"Waldner, M. J. et al. Multispectral optoacoustic tomography in Crohn\u2019s disease: noninvasive imaging of disease activity. Gastroenterology 151, 238\u2013240 (2016).","journal-title":"Gastroenterology"},{"key":"52143_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2023.100578","volume":"35","author":"AP Regensburger","year":"2024","unstructured":"Regensburger, A. P. et al. Multispectral optoacoustic tomography enables assessment of disease activity in paediatric inflammatory bowel disease. Photoacoustics 35, 100578 (2024).","journal-title":"Photoacoustics"},{"key":"52143_CR69","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/rheumatology\/keac346","volume":"62","author":"K Tascilar","year":"2023","unstructured":"Tascilar, K. et al. Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography. Rheumatology 62, 841\u2013849 (2023).","journal-title":"Rheumatology"},{"key":"52143_CR70","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jcmg.2022.11.010","volume":"16","author":"JS Gunther","year":"2023","unstructured":"Gunther, J. S. et al. Targeting muscular hemoglobin content for classification of peripheral arterial disease by noninvasive multispectral optoacoustic tomography. JACC Cardiovasc. Imaging 16, 719\u2013721 (2023).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"52143_CR71","doi-asserted-by":"publisher","first-page":"317ra199","DOI":"10.1126\/scitranslmed.aad1278","volume":"7","author":"I Stoffels","year":"2015","unstructured":"Stoffels, I. et al. Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Sci. Transl. Med. 7, 317ra199 (2015).","journal-title":"Sci. Transl. Med."},{"key":"52143_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.pacs.2021.100241","volume":"22","author":"J Grohl","year":"2021","unstructured":"Grohl, J., Schellenberg, M., Dreher, K. & Maier-Hein, L. Deep learning for biomedical photoacoustic imaging: a review. Photoacoustics 22, 100241 (2021).","journal-title":"Photoacoustics"},{"key":"52143_CR73","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo, D. & Richardson, S. The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J. Am. Geriatr. Soc. 39, 142\u2013148 (1991).","journal-title":"J. Am. Geriatr. Soc."},{"key":"52143_CR74","doi-asserted-by":"crossref","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166, 111\u2013117 (2002).","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"52143_CR75","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1177\/0883073889004001S15","volume":"4","author":"J Heckmatt","year":"1989","unstructured":"Heckmatt, J., Rodillo, E., Doherty, M., Willson, K. & Leeman, S. Quantitative sonography of muscle. J. Child Neurol. 4, S101\u2013S106 (1989).","journal-title":"J. Child Neurol."},{"key":"52143_CR76","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S0022-3476(82)80286-2","volume":"101","author":"JZ Heckmatt","year":"1982","unstructured":"Heckmatt, J. Z., Leeman, S. & Dubowitz, V. Ultrasound imaging in the diagnosis of muscle disease. J. Pediatr. 101, 656\u2013660 (1982).","journal-title":"J. Pediatr."},{"key":"52143_CR77","doi-asserted-by":"crossref","unstructured":"Waldner, M. J. et al. Multispectral optoacoustic tomography in Crohn\u2019s disease: non-invasive imaging of disease activity. Gastroenterology 151, 238\u2013240 (2016).","DOI":"10.1053\/j.gastro.2016.05.047"},{"key":"52143_CR78","doi-asserted-by":"crossref","unstructured":"G\u00fcnther, J. S. et al. Targeting muscular hemoglobin content for classification of peripheral arterial disease by noninvasive multispectral optoacoustic tomography. JACC Cardiovasc. Imaging 16, 719\u2013721 (2023).","DOI":"10.1016\/j.jcmg.2022.11.010"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52143-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:01:12Z","timestamp":1732726872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52143-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52143"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52143-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3731485\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]},"assertion":[{"value":"9 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P.R. and F.K. are co-inventors together with iThera Medical GmbH, Germany, on an EU patent application (EP 19 163 304.9) relating to a device and a method for analyzing optoacoustic data, an optoacoustic system and a computer program. F.K. is a member of the advisory board of iThera Medical GmbH, Munich, Germany. A.P.R. and F.K. received travel support from iThera Medical GmbH, Germany. A.P.R., A.L.W., and F.K. report travel support from Sanofi Aventis, Germany. A.P.R. and F.K. report lecture fees from Sanofi Genzyme. F.K. reports lecture fees from Siemens Healthcare GmbH. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7843"}}